AstraZeneca plc (LON: AZN, Nasdaq: AZN), a UK-based pharmaceutical and biopharmaceutical company, is reportedly launching an innovation program in South Korea aimed at fostering innovative collaborations and facilitating entry into the Chinese market. The company is currently accepting applications for the program until October 11, with the AZ K-Bio Expressway open innovation event scheduled for November 4, 2024.
The program, which is supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute, also aims to support the entry of Korean firms into the Chinese market. AstraZeneca will offer winning applicants access to its global advisory network, including the iCampus innovation hub in China. The program is open to a wide range of participants, including biotech firms involved in drug development or disease prediction diagnostics, mid-sized and large pharmaceutical companies seeking to expand into China, IT firms developing healthcare data or AI solutions, and companies operating in the pharmaceutical materials and components sectors.- Flcube.com
